HTATSF1 and breast neoplasm: We propose that targeting CK2 or disrupting the molecular interface of HTATSF1–TOPBP1 may be a promising therapeutic strategy for the treatment of CK2–HTATSF1–TOPBP1–proficient breast tumors.